FirstLook Lung is a blood-based test that helps identify lung cancer risk before or alongside LDCT, for USPSTF-eligible adults. From DELFI Diagnostics. Backed by Menlo.
About the role
As Sr. Research Associate, you will play a critical role in developing and validating next-generation sequencing assays from concept through commercial launch, working within a collaborative environment of scientists, engineers, and bioinformaticians. You will contribute to product development, verification, and validation activities for NGS-based laboratory tests for early cancer detection. Found on 1752vc Careers, the job board for startup and VC roles.
What they're looking for
- BS with 3-4 years of experience, or MS with 2-3 years relevant field (e.g., biomedical engineering, molecular biology, genetics, or genomics) in assay development for the life science industry
- Ability to work day shift 7:30AM - 4PM during training and then PM shift 4PM to 12AM for up to 3 months during January - March
- Proven ability to thoughtfully troubleshoot, communicate and escalate while working with limited support on a PM shift
- Proficient in high-throughput manual laboratory techniques, including precision pipetting for large-scale sample processing
- Proven track record in laboratory NGS execution and addressing technical challenges specific to nucleic acid extraction and library preparation for NGS
- Strong analytical skills with demonstrated ability to work independently
More about this role
DELFI Diagnostics, Inc. (DELFI Diagnostics) is developing next-generation, blood-based tests that are reliable, accessible and deliver a new way to help detect cancer. Employing advanced machine-learning methods to whole-genome sequencing data, the DELFI ("DNA EvaLuation of Fragments for early Interception") platform is built to address the highest-burden health challenges. DELFI Diagnostics prioritizes solutions that have the potential to save lives on a global scale, including for historically underserved populations. DELFI Diagnostics’ platform relies on fragmentomics – the discovery that cancer cells are more chaotic than normal cells and, when they die, leave behind tell-tale patterns and characteristics of cell-free DNA (cfDNA) fragments. FirstLook Lung, for individuals eligible for lung cancer screening, is DELFI Diagnostics’ first laboratory-developed screening test and can be part of routine blood work. FirstLook Lung uses millions of data points to reliably identify individuals who may have cancer detected through low-dose CT, including early stage disease with a negative predictive value of 99.8 percent. This test has not been cleared or approved by the FDA.
In our...
Browse similar: Startup jobs · San Francisco Bay Area